The GOG Highlight Reel – July 2025
Activity Overview
The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. A twice-yearly event, join us on Saturday, July 26, 2025, in Washington D.C. alongside the 2025 NRG Oncology Summer Meeting.
The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians to comprehend the evolving treatment landscape, including understanding available trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging approved therapies and investigational agents, providing insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the analytical skills to navigate the latest oncology research and clinical care confidently.
The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: Acrivon, AstraZeneca, Gilead
The GOG Foundation, Inc. would also like to thank our sponsors for this symposium: Pfizer Oncology, GSK, and Verastem
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Learning Objectives
Upon completion of the activities in this series, learners will demonstrate:
Increased knowledge regarding:
-
- The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers.
- The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers.
- The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers.
Greater competence related to:
-
- Understanding the available and selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers.
- Interpret and understand the application of recent data into clinical practice.
- Learn about current clinical trials in gynecologic cancers and understand what opportunities exist in the public domain.
Agenda
The GOG Highlight Reel Educational Series – July 2025
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The GOG Foundation, Inc. designates this internet live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.
NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.